LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Tamer Coşkun(Eli Lilly (United States)), Shweta Urva(Eli Lilly (United States)), William C. Roell(Eli Lilly (United States)), Hongchang Qu(Eli Lilly (United States)), Corina Loghin(Eli Lilly (United States)), Julie S. Moyers(Eli Lilly (United States)), Libbey S. O’Farrell(Eli Lilly (United States)), Daniel A. Briere(Eli Lilly (United States)), Kyle W. Sloop(Eli Lilly (United States)), Melissa K. Thomas(Eli Lilly (United States)), Valentina Pirro(Eli Lilly (United States)), David B. Wainscott(Eli Lilly (United States)), Francis S. Willard(Eli Lilly (United States)), Matthew Abernathy(Eli Lilly (United States)), LaRonda L. Morford(Eli Lilly (United States)), Yu Du(Eli Lilly (United States)), Charles Benson(Eli Lilly (United States)), Ruth E. Gimeno(Eli Lilly (United States)), Axel Haupt(Eli Lilly (United States)), Zvonko Miličević
Cited by 267Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis